NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaResearch in context

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaResearch in context

Summary: Background: The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy with no standard second-line (2L) treatment. Methods: Patient...

Full description

Bibliographic Details
Main Authors: Mairéad G. McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sharmila Sothi, Alan Anthoney, Christopher Bell, Alkesh Patel, Jamie B. Oughton, David A. Cairns, Wasat Mansoor, Angela Lamarca, Richard A. Hubner, Juan W. Valle
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:EClinicalMedicine
Subjects:
Neuroendocrine carcinoma
Second-line treatment
Liposomal irinotecan
Docetaxel
Quality of life
Online Access:http://www.sciencedirect.com/science/article/pii/S258953702300192X

Similar Items

Similar Items